Loading…
Lobbying Income
$60K
Filings
3
Unique Clients
1
Active Period
2015
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
2015 · second_quarter · Client: EISAI, INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of obesity Rx products H Con Res 27 - Establishing the budget for the United States Government for FY 2016 and setting forth appropriate budgetary levels for FYs 2017 through 2025. S Con Res 11 - An original concurrent resolution setting forth the congressional budget for the United States Government for Fiscal Year 2016 and setting for the appropriate budgetary levels for fiscal years 2017 through 2025.
Client expense: — · Firm income: $30,000
Matched citations: H Con Res 27
SGR Repeal and Medicare Provider Payment Modernization Act of 2015
2015 · second_quarter · Client: EISAI, INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. Medicare Access and CHIP Reauthorization Act of 2015 (HR2) SGR Repeal and Medicare Provider Payment Modernization Act of 2015 (S810/HR1470) Treat and Reduce Obesity Act of 2015 (HR2404)
Client expense: — · Firm income: $30,000
Matched citations: HR1470
National Defense Authorization Act for Fiscal Year 2016
2015 · second_quarter · Client: EISAI, INC.
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S1376) Department of Defense Appropriations Bill for 2016 (HR2685)
Client expense: — · Firm income: $30,000
Matched citations: HR 1735
Medicare Access and CHIP Reauthorization Act of 2015
2015 · second_quarter · Client: EISAI, INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. Medicare Access and CHIP Reauthorization Act of 2015 (HR2) SGR Repeal and Medicare Provider Payment Modernization Act of 2015 (S810/HR1470) Treat and Reduce Obesity Act of 2015 (HR2404)
Client expense: — · Firm income: $30,000
Matched citations: HR2
Treat and Reduce Obesity Act of 2015
2015 · second_quarter · Client: EISAI, INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. Medicare Access and CHIP Reauthorization Act of 2015 (HR2) SGR Repeal and Medicare Provider Payment Modernization Act of 2015 (S810/HR1470) Treat and Reduce Obesity Act of 2015 (HR2404)
Client expense: — · Firm income: $30,000
Matched citations: HR2404
Department of Defense Appropriations Act, 2016
2015 · second_quarter · Client: EISAI, INC.
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S1376) Department of Defense Appropriations Bill for 2016 (HR2685)
Client expense: — · Firm income: $30,000
Matched citations: HR2685
Improving Regulatory Transparency for New Medical Therapies Act
2015 · second_quarter · Client: EISAI, INC.
DEA scheduling of controlled substances Improving Regulatory Transparency for New Medical Therapies Act (H.R. 639/S. 481)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 639
National Defense Authorization Act for Fiscal Year 2016
2015 · second_quarter · Client: EISAI, INC.
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S1376) Department of Defense Appropriations Bill for 2016 (HR2685)
Client expense: — · Firm income: $30,000
Matched citations: S1376
Improving Regulatory Transparency for New Medical Therapies Act
2015 · second_quarter · Client: EISAI, INC.
DEA scheduling of controlled substances Improving Regulatory Transparency for New Medical Therapies Act (H.R. 639/S. 481)
Client expense: — · Firm income: $30,000
Matched citations: S. 481
SGR Repeal and Medicare Provider Payment Modernization Act of 2015
2015 · second_quarter · Client: EISAI, INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. Medicare Access and CHIP Reauthorization Act of 2015 (HR2) SGR Repeal and Medicare Provider Payment Modernization Act of 2015 (S810/HR1470) Treat and Reduce Obesity Act of 2015 (HR2404)
Client expense: — · Firm income: $30,000
Matched citations: S810
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025.
2015 · second_quarter · Client: EISAI, INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of obesity Rx products H Con Res 27 - Establishing the budget for the United States Government for FY 2016 and setting forth appropriate budgetary levels for FYs 2017 through 2025. S Con Res 11 - An original concurrent resolution setting forth the congressional budget for the United States Government for Fiscal Year 2016 and setting for the appropriate budgetary levels for fiscal years 2017 through 2025.
Client expense: — · Firm income: $30,000
Matched citations: S Con Res 11
Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
2015 · first_quarter · Client: EISAI, INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of obesity Rx products H Con Res 27 - Establishing the budget for the United States Government for FY 2016 and setting forth appropriate budgetary levels for FYs 2017 through 2025. S Con Res 11 - An original concurrent resolution setting forth the congressional budget for the United States Government for Fiscal Year 2016 and setting for the appropriate budgetary levels for fiscal years 2017 through 2025.
Client expense: — · Firm income: $30,000
Matched citations: H Con Res 27
SGR Repeal and Medicare Provider Payment Modernization Act of 2015
2015 · first_quarter · Client: EISAI, INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. Medicare Access and CHIP Reauthorization Act of 2015 (HR2) SGR Repeal and Medicare Provider Payment Modernization Act of 2015 (S810/HR1470) Treat and Reduce Obesity Act of 2015 (HR2404)
Client expense: — · Firm income: $30,000
Matched citations: HR1470
National Defense Authorization Act for Fiscal Year 2016
2015 · first_quarter · Client: EISAI, INC.
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S1376) Department of Defense Appropriations Bill for 2016 (HR2685)
Client expense: — · Firm income: $30,000
Matched citations: HR 1735
Medicare Access and CHIP Reauthorization Act of 2015
2015 · first_quarter · Client: EISAI, INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. Medicare Access and CHIP Reauthorization Act of 2015 (HR2) SGR Repeal and Medicare Provider Payment Modernization Act of 2015 (S810/HR1470) Treat and Reduce Obesity Act of 2015 (HR2404)
Client expense: — · Firm income: $30,000
Matched citations: HR2
Treat and Reduce Obesity Act of 2015
2015 · first_quarter · Client: EISAI, INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. Medicare Access and CHIP Reauthorization Act of 2015 (HR2) SGR Repeal and Medicare Provider Payment Modernization Act of 2015 (S810/HR1470) Treat and Reduce Obesity Act of 2015 (HR2404)
Client expense: — · Firm income: $30,000
Matched citations: HR2404
Department of Defense Appropriations Act, 2016
2015 · first_quarter · Client: EISAI, INC.
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S1376) Department of Defense Appropriations Bill for 2016 (HR2685)
Client expense: — · Firm income: $30,000
Matched citations: HR2685
Improving Regulatory Transparency for New Medical Therapies Act
2015 · first_quarter · Client: EISAI, INC.
DEA scheduling of controlled substances Improving Regulatory Transparency for New Medical Therapies Act (H.R. 639/S. 481)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 639
National Defense Authorization Act for Fiscal Year 2016
2015 · first_quarter · Client: EISAI, INC.
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S1376) Department of Defense Appropriations Bill for 2016 (HR2685)
Client expense: — · Firm income: $30,000
Matched citations: S1376
Improving Regulatory Transparency for New Medical Therapies Act
2015 · first_quarter · Client: EISAI, INC.
DEA scheduling of controlled substances Improving Regulatory Transparency for New Medical Therapies Act (H.R. 639/S. 481)
Client expense: — · Firm income: $30,000
Matched citations: S. 481
SGR Repeal and Medicare Provider Payment Modernization Act of 2015
2015 · first_quarter · Client: EISAI, INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. Medicare Access and CHIP Reauthorization Act of 2015 (HR2) SGR Repeal and Medicare Provider Payment Modernization Act of 2015 (S810/HR1470) Treat and Reduce Obesity Act of 2015 (HR2404)
Client expense: — · Firm income: $30,000
Matched citations: S810
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025.
2015 · first_quarter · Client: EISAI, INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of obesity Rx products H Con Res 27 - Establishing the budget for the United States Government for FY 2016 and setting forth appropriate budgetary levels for FYs 2017 through 2025. S Con Res 11 - An original concurrent resolution setting forth the congressional budget for the United States Government for Fiscal Year 2016 and setting for the appropriate budgetary levels for fiscal years 2017 through 2025.
Client expense: — · Firm income: $30,000
Matched citations: S Con Res 11
Medicare Access and CHIP Reauthorization Act of 2015
2015 · first_quarter · Client: EISAI, INC.
Act (P.L. 113-54)Regulatory and legislative health care issues, including the 340B program; DEA scheduling of controlled substances H.R. 639/S. 481-Improving Regulatory Transparency for New Medical Therapies Act;Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs.H.R. 2- Medicare Access and CHIP Reauthorization Act of 2015 S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015; Potential pharmaceutical reimbursement cuts (offsets); Innovation Cures Initiative
Client expense: — · Firm income: —
Matched citations: H.R. 2
Medicare Access and CHIP Reauthorization Act of 2015
2015 · first_quarter · Client: EISAI, INC.
Act (P.L. 113-54)Regulatory and legislative health care issues, including the 340B program; DEA scheduling of controlled substances H.R. 639/S. 481-Improving Regulatory Transparency for New Medical Therapies Act;Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs.H.R. 2- Medicare Access and CHIP Reauthorization Act of 2015 S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015; Potential pharmaceutical reimbursement cuts (offsets); Innovation Cures Initiative
Client expense: — · Firm income: —
Matched citations: H.R. 2
Medicare Access and CHIP Reauthorization Act of 2015
2015 · first_quarter · Client: EISAI, INC.
Act (P.L. 113-54)Regulatory and legislative health care issues, including the 340B program; DEA scheduling of controlled substances H.R. 639/S. 481-Improving Regulatory Transparency for New Medical Therapies Act;Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs.H.R. 2- Medicare Access and CHIP Reauthorization Act of 2015 S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015; Potential pharmaceutical reimbursement cuts (offsets); Innovation Cures Initiative
Client expense: — · Firm income: —
Matched citations: H.R. 2
Source: Senate LDA